Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Genetic testing of early breast tumours could allow patients to go without chemo

Share :

2018 ASCO Annual Meeting

1 - 5 Jun 2018
Published: 3 Jun 2018
Views: 1571
Rating:
Save
Dr Joseph Sparano - Albert Einstein Cancer Center, New York, USA

Dr Sparano presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from the TAILORx trial.

The results show that 70% of women with early HR / HER2- breast cancer could be spared chemotherapy, based on the results from a 21gene assay.

For more on these results, watch his interview with ecancer and read our news coverage here.

Slides from this presentation are available here.

Related Videos

Hormonal receptor positive breast cancer adjuvant and metastatic indications
Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA
Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )
12 Jul 2024
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer ( Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal )
27 Oct 2023
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall...
Dr Neil Gross - MD Anderson Cancer Center, Houston, USA
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC ( Dr Neil Gross - MD Anderson Cancer Center, Houston, USA )
27 Oct 2023
The Southeast Asian Breast Cancer Symposium; background, aims and successes
Carolyn Taylor - Executive Director, Global Focus on Cancer
The Southeast Asian Breast Cancer Symposium; background, aims and successes ( Carolyn Taylor - Executive Director, Global Focus on Cancer )
5 Sep 2023
OncoAlert Round Up for August 25th - 31st, 2023
Dr Gil Morgan - Executive Director, OncoAlert
OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )
4 Sep 2023
OncoAlert Round Up for August 11th - 17th, 2023
Dr Gil Morgan - Executive Director, OncoAlert
OncoAlert Round Up for August 11th - 17th, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )
22 Aug 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...
Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )
2 May 2023
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small...
Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )
2 May 2023
The use of IORT at Universitätsmedizin Mannheim hospital
Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany
The use of IORT at Universitätsmedizin Mannheim hospital ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )
2 May 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation